C4 Therapeutics, Inc. Operating Expenses
C4 Therapeutics, Inc. (CCCC) reported Operating Expenses of $33.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- C4 Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $33.06M, a 5.43% decline year-over-year.
- C4 Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $33.94M, a 6.77% decline year-over-year.
- C4 Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $34.16M, a 20.34% decline year-over-year.
- C4 Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $45.64M, a 4.67% increase year-over-year.
- C4 Therapeutics, Inc. operating expenses for fiscal 2025 was $151.17M, a 2.60% decline from fiscal 2024.
- C4 Therapeutics, Inc. operating expenses for fiscal 2024 was $155.20M, a 2.87% decline from fiscal 2023.
- C4 Therapeutics, Inc. operating expenses for fiscal 2023 was $159.79M, a 0.52% decline from fiscal 2022.
- C4 Therapeutics, Inc. operating expenses for fiscal 2022 was $160.63M, a 25.57% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.06M 10-Q · filed 2026-08-11 | $67.00M 10-Q · filed 2026-08-11 | $101.16M derived: sum of 3 quarters · filed 2026-08-11 | $146.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $33.94M 10-Q · filed 2026-05-12 | $68.10M derived: sum of 2 quarters · filed 2026-05-12 | $113.74M derived: sum of 3 quarters · filed 2026-05-12 | $148.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $34.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $79.80M derived: sum of 2 quarters · filed 2026-02-26 | $114.77M derived: sum of 3 quarters · filed 2026-08-11 | $151.17M 10-K · filed 2026-02-26 |
| 2025-09-30 | $45.64M 10-Q · filed 2025-11-06 | $80.61M derived: sum of 2 quarters · filed 2026-08-11 | $117.01M 10-Q · filed 2025-11-06 | $159.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $34.96M 10-Q · filed 2026-08-11 | $71.37M 10-Q · filed 2026-08-11 | $114.25M derived: sum of 3 quarters · filed 2026-08-11 | $157.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $36.40M 10-Q · filed 2026-05-12 | $79.29M derived: sum of 2 quarters · filed 2026-05-12 | $122.89M derived: sum of 3 quarters · filed 2026-05-12 | $156.34M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $42.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $86.49M derived: sum of 2 quarters · filed 2026-02-26 | $119.94M derived: sum of 3 quarters · filed 2026-02-26 | $155.20M 10-K · filed 2026-02-26 |
| 2024-09-30 | $43.61M 10-Q · filed 2025-11-06 | $77.05M derived: sum of 2 quarters · filed 2025-11-06 | $112.31M 10-Q · filed 2025-11-06 | $153.00M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $33.45M 10-Q · filed 2025-08-07 | $68.71M 10-Q · filed 2025-08-07 | $109.39M derived: sum of 3 quarters · filed 2025-08-07 | $148.27M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $35.26M 10-Q · filed 2025-05-07 | $75.95M derived: sum of 2 quarters · filed 2025-05-07 | $114.83M derived: sum of 3 quarters · filed 2025-05-07 | $155.06M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $40.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $79.57M derived: sum of 2 quarters · filed 2025-02-27 | $119.80M derived: sum of 3 quarters · filed 2025-02-27 | $159.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $38.88M 10-Q · filed 2024-10-31 | $79.11M derived: sum of 2 quarters · filed 2024-10-31 | $119.10M 10-Q · filed 2024-10-31 | $160.25M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $40.23M 10-Q · filed 2024-08-01 | $80.22M 10-Q · filed 2024-08-01 | $121.37M derived: sum of 3 quarters · filed 2024-08-01 | $160.61M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $39.99M 10-Q · filed 2024-05-08 | $81.13M derived: sum of 2 quarters · filed 2024-05-08 | $120.38M derived: sum of 3 quarters · filed 2024-05-08 | $161.59M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $41.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $80.39M derived: sum of 2 quarters · filed 2024-02-22 | $121.61M derived: sum of 3 quarters · filed 2024-02-22 | $160.63M 10-K · filed 2024-02-22 |
| 2022-09-30 | $39.24M 10-Q · filed 2023-11-01 | $80.46M derived: sum of 2 quarters · filed 2023-11-01 | $119.48M 10-Q · filed 2023-11-01 | $154.82M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $41.22M 10-Q · filed 2023-08-08 | $80.24M 10-Q · filed 2023-08-08 | $115.57M derived: sum of 3 quarters · filed 2023-08-08 | $148.33M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $39.02M 10-Q · filed 2023-05-04 | $74.36M derived: sum of 2 quarters · filed 2023-05-04 | $107.11M derived: sum of 3 quarters · filed 2023-05-04 | $139.01M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $35.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $68.09M derived: sum of 2 quarters · filed 2023-02-23 | $99.98M derived: sum of 3 quarters · filed 2023-02-23 | $127.92M 10-K · filed 2023-02-23 |
| 2021-09-30 | $32.75M 10-Q · filed 2022-11-03 | $64.65M derived: sum of 2 quarters · filed 2022-11-03 | $92.59M 10-Q · filed 2022-11-03 | $119.75M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $31.90M 10-Q · filed 2022-08-04 | $59.83M 10-Q · filed 2022-08-04 | $87.00M derived: sum of 3 quarters · filed 2022-08-04 | $113.79M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $27.93M 10-Q · filed 2022-05-05 | $55.10M derived: sum of 2 quarters · filed 2022-05-05 | $81.90M derived: sum of 3 quarters · filed 2022-05-05 | $102.42M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $27.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $53.96M derived: sum of 2 quarters · filed 2022-02-24 | $74.49M derived: sum of 3 quarters · filed 2022-02-24 | $93.64M 10-K · filed 2022-02-24 |
| 2020-09-30 | $26.80M 10-Q · filed 2021-11-10 | $47.33M derived: sum of 2 quarters · filed 2021-11-10 | $66.48M 10-Q · filed 2021-11-10 | $85.19M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $20.53M 10-Q · filed 2021-08-11 | $39.68M 10-Q · filed 2021-08-11 | $58.39M derived: sum of 3 quarters · filed 2022-02-24 | $73.76M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $19.15M 10-Q · filed 2021-05-13 | $37.86M derived: sum of 2 quarters · filed 2022-02-24 | $53.23M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $18.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $34.07M derived: sum of 2 quarters · filed 2022-02-24 | $56.83M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $15.37M 10-Q · filed 2020-11-12 | $38.13M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |